Efficacy of Janus kinase inhibitors in adult patients with alopecia areata

International Journal of Research in Dermatology Pub Date : 2023-08-24 DOI:10.18203/issn.2455-4529.intjresdermatol20232552

Andrea Sierra Franco, Paulina García De León Flores, Paola Scarlett Díaz De Alba, María Jimena Talamante Madrid, Cassandra Espinosa Rodríguez, Renata Monserrat Espejo Nuño

{"title":"Efficacy of Janus kinase inhibitors in adult patients with alopecia areata","authors":"Andrea Sierra Franco, Paulina García De León Flores, Paola Scarlett Díaz De Alba, María Jimena Talamante Madrid, Cassandra Espinosa Rodríguez, Renata Monserrat Espejo Nuño","doi":"10.18203/issn.2455-4529.intjresdermatol20232552","DOIUrl":null,"url":null,"abstract":"Alopecia areata (AA) is a chronic, immune-mediated disorder resulting in localized hair loss due to targeting hair follicle epithelium. The authors aimed to summarize the existing literature on patients with AA who underwent treatment with Janus kinase inhibitors (JAKis) and discuss the current evidence regarding their efficacy and safety. An extensive scientific literature search was conducted between January 1, 2017, and April 16, 2023, using a recognized medical and scientific database. The extracted data were synthesized and analyzed, focusing on the effect of JAKis in reducing hair loss in adult patients with AA. The evidence suggests that oral JAKis such as tofacitinib, ruxolitinib, and Baricitinib show promise in treating AA regarding both efficacy and safety. The group of drugs JAKis are a good treatment option even in severe clinical conditions of AA, further investigation should be taken to consideration including dosage and treatment duration.","PeriodicalId":14331,"journal":{"name":"International Journal of Research in Dermatology","volume":"31 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Research in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/issn.2455-4529.intjresdermatol20232552","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Alopecia areata (AA) is a chronic, immune-mediated disorder resulting in localized hair loss due to targeting hair follicle epithelium. The authors aimed to summarize the existing literature on patients with AA who underwent treatment with Janus kinase inhibitors (JAKis) and discuss the current evidence regarding their efficacy and safety. An extensive scientific literature search was conducted between January 1, 2017, and April 16, 2023, using a recognized medical and scientific database. The extracted data were synthesized and analyzed, focusing on the effect of JAKis in reducing hair loss in adult patients with AA. The evidence suggests that oral JAKis such as tofacitinib, ruxolitinib, and Baricitinib show promise in treating AA regarding both efficacy and safety. The group of drugs JAKis are a good treatment option even in severe clinical conditions of AA, further investigation should be taken to consideration including dosage and treatment duration.

查看原文本刊更多论文

Janus激酶抑制剂治疗成年斑秃的疗效

斑秃(AA)是一种慢性、免疫介导的疾病，由于靶向毛囊上皮而导致局部脱发。作者的目的是总结现有文献中关于接受Janus激酶抑制剂(JAKis)治疗的AA患者，并讨论目前关于其有效性和安全性的证据。在2017年1月1日至2023年4月16日期间，使用公认的医学和科学数据库进行了广泛的科学文献检索。对提取的数据进行综合分析，重点研究JAKis在减少成年AA患者脱发中的作用。有证据表明，口服JAKis如托法替尼、鲁索利替尼和Baricitinib在治疗AA的有效性和安全性方面都有希望。即使在严重的AA临床情况下，JAKis组药物也是一种很好的治疗选择，但剂量和治疗时间等需要进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Research in Dermatology

自引率

0.00%

发文量